Comparing two anemia medicines for kidney disease patients
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have chronic kidney disease stage 3, 4, or 5 (moderate to severe kidney damage).
- You are not currently on dialysis.
- Your hemoglobin level is between 8 and 10 g/dL (low, but not dangerously low).
- Your iron levels are adequate (ferritin over 100 and transferrin saturation over 20%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking an oral pill three times a week (vadadustat) works as well as injections (Epogen) to treat anemia—low red blood cells—in people on dialysis. If it works, a pill might be easier and more convenient than injections.
This trial tests two similar medicines that help your body make red blood cells. It is for people with advanced chronic kidney disease who are on dialysis, and aims to see if the study medicine works as well as the standard one.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests a new oral medication (QLG1218, also called daprodustat) to treat anemia in people with chronic kidney disease who are on hemodialysis. It is comparing the new drug to the usual injected ESA medicines to see if it works as well or better.
This study looks at how well Daprodustat works for anemia in people with chronic kidney disease, including those on dialysis or after a kidney transplant. It collects real-world data to help doctors manage this condition.
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
Hear when a new Chronic Kidney Disease (Stages 3b-5) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.